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Abstract 
 The oral cavity contains many different surfaces all colonized by prokaryotes, of 
which over 700 have been identified. While almost all people have some degree of plaque 
formation, the more concerning diseases of caries, candidiasis and periodontal disease afflict 
many patients and represent a major public health concern. As these are all diseases which 
have a component attributable to parts of the microbiota, efforts to manipulate the microbes 
has until recently involved use of antimicrobial agents. However, due to side effects, 
resistance and failure to restore homeostasis, this approach is limited. As an alternative, the 
administration of beneficial microbes (probiotics) has been considered. In this thesis, 
probiotic Streptococcus salivarius K12 and M18 and their by-products were shown to 
interfere with adhesion and coaggregation of pathogenic bacteria and yeast, and lower 
inflammatory factors.  A human trial of healthy subjects showed the probiotics to be safe and 
not induce inflammation or disrupt the indigenous microbiota.  
  
Keywords: oral cavity, probiotic, Streptococcus salivarius, adhesion, inflammation, 
coaggregation, humans  
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Chapter 1  
1 Introduction 
 
1.1 Focus of Thesis 
 The purpose of this study was to investigate the ability of the human commensal 
bacterial species Streptococcus salivarius to maintain homeostasis in the oral cavity. This 
section will cover information on the human oral microbiome, how diseases develop as 
this bacterial community shifts in composition, and how probiotics may offer promise in 
preventing and treating these highly prevalent oral diseases, with specific emphasis 
placed on the oral probiotic strains S. salivarius K12 and M18. 
  
1.2 The Human Microbiome 
 The human body plays host to numerous bacterial populations which colonize and 
persist at various sites including the skin, gastrointestinal tract, vagina, urogenital tract, 
and oral cavity (1). These complex and diverse communities are established and 
influenced based on a variety of factors such as the host's genetics, behaviours, 
environment, and diet (2). The human microbiome, defined as the collective genomes of 
our microbial constituents, provide additional metabolic functions above and beyond 
what the human genome alone is capable of driving (3).  It has been increasingly 
recognized that these microorganisms dynamically interact with the host in ways that can 
have profound effects on health and disease (1, 2). Perhaps nowhere is the association of 
commensal microbes with our well-being more apparent than in the oral cavity.  
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1.3 Healthy Oral Microbiome 
 The oral cavity contains many different surfaces including the teeth, tongue, 
cheeks, hard and soft palates, gingival sulcus (area of space between a tooth and the 
surrounding gingival tissue), and tonsils, which are colonized by distinct and intricate 
microbial communities (4). Early research focused on culturing the vast number of 
bacterial species inhabiting this environment, with many aerobes as well as facultative 
and obligate anaerobes isolated and identified. These organisms demonstrated a wide 
range of metabolic processes, including the ability to degrade and utilize the complex 
sugars and proteins consumed by their human host in their diet (5). However, it is well 
established that a significant percentage of bacteria cannot be grown in the laboratory 
using traditional culture methods (6). The advancement of non-culture based methods of 
detection and classification in recent years, including high-throughput next generation 
sequencing technologies, has shed light on the truly immense range of bacterial species 
that colonize and persist in the human oral cavity (4, 7, 8). Approximately 700 oral 
prokaryotic species have currently been identified, of which 34% are presently 
uncultivated (4). The existence of such microorganisms is not unique to the oral cavity, as 
uncultivated species have been shown to represent around 40-50% of the total taxa 
colonizing the human skin, vagina, and stomach (9). Studies have identified a healthy 
"core microbiome" consisting predominantly of taxa belonging to Firmicutes, 
Proteobacteria, Actinobacteria, Bacteroidetes, and Fusobacteria phyla (10). These 
commensals preserve homeostasis in the oral cavity by helping to produce nutrients, 
maintain pH, modulate saliva production, and generate inhibitory substances, all of which 
act to prevent colonisation and growth of exogenous or pathogenic species (11).   
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1.4 Diseases caused by the Disruption of the Oral Microbiome 
 While the oral microbiome of an individual remains fairly stable over time (12), 
problems arise when bacterial populations shift, allowing different metabolic processes to 
occur, often resulting in a drastically altered local environment. The resulting oral 
diseases can have a significant negative impact on the quality of life of the patient, and 
often result in chronic conditions, particularly if access to dental professionals is limited. 
Some of the most prevalent oral microbial associated diseases are summarized below.  
   
1.4.1 Dental Caries  
 Dental caries (otherwise known as tooth decay or cavities) is one of the most 
prevalent chronic diseases of people worldwide, with patients susceptible to developing 
caries throughout their lifetime (13). This process is mediated by an increase in 
acidogenic and/or acid-tolerating bacteria found in dental plaques (biofilms) on the teeth, 
which ferment sugars into organic acids (14). The consequent reduction in pH catalyzes 
the demineralization of enamel, dentin and cementum in teeth, resulting in caries lesions 
(13). Production of short-chain carboxylic acids by Streptococci and Lactobacilli – 
chiefly lactic acid production by Streptococcus mutans – is the primary etiology of caries, 
however other bacteria with similar properties such as Actinomyces, Bifidobacteria, 
Atopobium, Propionibacterium, and Veillonella can contribute (15).  
 Management of caries in dental practice has traditionally and mainly been carried 
out through surgical methods (16). The demineralized/diseased tooth structure is removed 
and restorative materials are applied to promote reformation. This, however, does not 
remove the causative infectious agent. Broad-spectrum antibiotics and antimicrobials are 
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occasionally used post-surgery to suppress further infection, however any success will be 
temporary (16). 
 
1.4.2 Oral Candidiasis 
 Oral candidiasis is a fungal infection of the oral cavity caused by various species 
of yeast from the genus Candida. Candida species are frequently found in the oral cavity 
of healthy individuals, with a recent study detecting the genera in 75% of participants 
(17). The most common isolate found in humans is Candida albicans, which colonizes 
the posterior dorsum of the tongue (18). While typically carried asymptomatically, C. 
albicans can act as an opportunistic pathogen in patients with compromised oral health or 
immune deficiencies, such as the elderly or transplant recipients (19). While oral lesions 
caused by C. albicans infection can cause discomfort, in more serious cases the yeast can 
gain access to the bloodstream and systemically spread (20). Proper oral hygiene 
practices are important for controlling natural oral yeast populations, with antifungal 
agents used as treatment once oral candidiasis has been established (19).  
  
1.4.3 Periodontal Disease 
 Periodontal disease is characterized by inflammation of the tissues that surround 
and support the teeth, including the gums and periodontal ligaments. It arises as a 
consequence of long-term dental plaque build up on the teeth. This plaque is made up of 
bacteria and food debris, which eventually turns into a hard deposit (tartar) if not 
removed by regular brushing and flossing. The bacteria trapped in the tartar irritate the 
gums, causing an overt immune response directed against them, leading to inflammation 
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(21). Symptoms of periodontal disease include bleeding, swelling, and tenderness of the 
gums. In more advanced cases, such as periodontitis, alveolar bone that surrounds and 
supports the teeth is destroyed, which can lead to tooth loss. A recent study indicated that 
approximately 50% of North American adults suffer from some form of periodontal 
disease, making it a major public health concern (22).  
 During periodontal disease, the oral microbiota shifts  from a Gram-positive 
dominated community to one comprised mainly of Gram-negative bacteria (23). Bacteria 
classically considered to be strongly associated with periodontal disease include 
Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Fusobacterium 
nucleatum (24). These anaerobes trigger the release of pro-inflammatory cytokines, 
leading to immune cell recruitment, tissue destruction, and eventual bone loss. Cytokines 
important in this destructive cycle include IL-1β (bone resorption, metalloproteinase 
production), IL-6 (B-cell activation), IL-8 (attraction and activation of neutrophils), TNF-
α (bone resorption), and IFN-γ (modulates local immune responses) (25).    
 When periodontal disease is diagnosed, plaque and tartar is typically removed by 
a dental professional in a process known as "scaling". In more advanced cases, surgery 
may be required to allow deep cleaning and reduce periodontal pocket depth. Newer 
therapies aimed at periodontal regeneration include the use of soft tissue and bone grafts, 
guided tissue/bone regeneration, and the delivery of growth factors by implanted 
biomaterials (26). Management of periodontal disease typically requires multiple trips per 
year to the dentist for cleanings, and even with regular home oral care inflammation may 
return (21).  
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1.4.4 Influence at Distant Sites 
 The effects of a disruption of the oral microbiome are not confined solely to the 
oral cavity. Members of the oral microbiota can have a bearing upon heart health, 
Streptococcus pyogenes being the classic example, where cross reactive antibodies affect 
the heart valves and other parts of the body (27). Periodontal disease has been associated 
with cardiovascular disease through a variety of epidemiological studies, and meta-
analyses combining the findings from multiple independent studies conducted since the 
1950's (28, 29).  The increase in gingival bleeding during periodontal disease offers oral 
bacteria access to the bloodstream, where they can circulate and interact with 
atheromatous plaque deposits. Numerous studies have detected oral bacterial DNA in 
atherosclerotic lesions (30). The bacteria appear capable of invading and activating 
endothelial cells, increasing Toll-like receptor (TLR) interactions, or inducing the 
expression of metalloproteinases, all of which contribute to the development of 
cardiovascular disease (31).  
             In summary, disruptions of the oral microbiome are not only common, but can 
result in debilitating and chronic diseases for patients in the oral cavity and at distal body 
sites as well. Identifying novel ways to help prevent, manage, and treat such diseases 
remains a focus for researchers and clinicians worldwide, with the use of probiotics 
offering a promising avenue for tackling these conditions.  
   
1.5 Probiotics 
 Probiotics are defined as live microorganisms that when administered in adequate 
amounts confer a health benefit on the host (32). Of the many clinical studies showing the 
ability of probiotics to prevent and treat local and distant site condition (32, 33),  the 
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effects are mostly strain specific. There are a number of ways in which probiotics interact 
with the host, including competition with other organisms, epithelial cross talk with the 
host immune system, improving the integrity of epithelial barriers and function of tight 
junctions, and production of many metabolites, enzymes, co-factors, and vitamins  K, B2, 
B12, and folate, all of which are utilized by the host (33–38).  
 
1.5.1 Probiotics for Dentistry 
 The ability of probiotics to help maintain a healthy oral cavity or manage and treat 
oral diseases has been increasingly examined in recent years. As oral disease is the fourth 
most expensive disease to treat worldwide (39), regular probiotic usage may offer the 
opportunity to economically complement  visits with trained dental professionals. Dental 
caries, traditionally associated with the species Streptococcus mutans, has been targeted 
by a variety of health-associated bacteria. Studies have demonstrated that consumption of 
Lactobacillus rhamnosus in cheese (40), Lactobacillus reuteri in tablets/straws (41), and 
Bifidobacterium in yogurt (42) are capable of reducing salivary S. mutans counts. 
Interestingly, these Lactobacillus and Bifidobacterium species are usually recognized as 
dietary probiotics aimed at improving gastrointestinal health, and have been derived from 
the intestinal tract. As such, it has been suggested that using bacteria that traditionally 
colonize the oral cavity may offer a better chance to impact oral health parameters. An 
interesting strategy along this line has been designed by Hillman and coworkers, who 
isolated a strain of S. mutans from a human subject capable of producing a bacteriocin 
with potent activity against virtually all other S. mutans strains (43). This strain was able 
to stably colonize the oral cavity of human volunteers, and resulted in an overall decrease 
8 
 
of S. mutans levels (44). In an effort to reduce its cariogenic potential, this group 
successfully deleted the lactate dehydrogenase operon from the bacterial genome, then 
demonstrated that the resulting mutant strain resulted in a lower incidence of dental caries 
development in rat infection models compared to the wild type strain (45). As lactic acid 
production is presumed to be the driving pathogenic mechanism behind the development 
of cariogenic lesions, this S. mutans strain offers intriguing potential for "replacement 
therapy", where indigenous, potentially pathogenic bacterial species are eliminated from 
their ecological niche and replaced with a strain designed to prevent oral damage (46). 
Future oral probiotic development may be well served by following a similar approach; 
identifying and isolating potential beneficial species from healthy volunteers, determining 
colonization potential, and engineering the strain to generate favourable 
products/eliminate harmful ones.    
 Another oral health related condition that has been tackled by probiotics is 
halitosis (bad breath). Driven mainly by the production of volatile sulfur compounds 
(VSCs) by bacteria (particularly Gram negative anaerobes, including P. gingivalis and 
Prevotella intermedia) colonizing the tongue (47), it is believed to affect a large 
proportion of the population to various degrees. Traditional treatment options have 
focussed on the non-specific elimination of oral bacteria by various anti-bacterial 
chemical therapies. However, such efforts are costly and provide short-term relief, as 
malodour generating bacteria quickly return when treatment is ceased (48). In one 
probiotic study, healthy individuals who gargled a solution containing a Weissella cibaria 
isolate (selected based on its observed hydrogen peroxide generating ability in vitro) had 
lower VSC levels the following day than those who gargled a solution of distilled water 
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(49). Probiotics designed to treat periodontal disease have also been tested with 
promising results. Teughels et al. recently examined the daily usage of lozenges 
containing Lactobacillus reuteri by patients suffering from chronic periodontitis 
following standard dental scaling and root planing (50). Probiotic consumption resulted 
in significantly more pocket depth reduction and attachment gain in deep periodontal 
pockets, as well as  a decrease in P. gingivalis levels, compared to those subjects who 
received a placebo lozenge. A similar study using Lactobacillus salivarius WB21-
containing tablets demonstrated the ability of this probiotic to reduce the plaque index 
and periodontal pocket depth in subjects at high risk of periodontal disease (51). 
 While the above examples clearly demonstrate that a variety of bacterial species 
and strains have been used successfully as probiotics in dentistry, our research focused 
specifically on the oral species Streptococcus salivarius, and ways that it could be applied 
to help maintain homeostasis in the oral cavity.    
 
1.6 Streptococcus salivarius K12 and M18 
 Streptococcus salivarius is a Gram-positive bacterial commensal which colonizes 
the human oral cavity throughout the host's life, and is generally associated with health 
(52). These characteristics made this species attractive to investigate as a potential oral 
probiotic. S. salivarius strains K12 and M18 were selected for further study based on 
their in vitro inhibitory activity against Streptococcus pyogenes (53). Both strains encode 
multiple bacteriocins; bacterially produced substances with the capacity to either inhibit 
other bacteria attempting to colonize the same niche, or to act as signaling molecules. S. 
salivarius K12 produces the bacteriocins Salivaricin A2 and Salivaricin B (54), while 
M18 produces Salivaricin A2, Salivaricin 9, and the bacteriocin MPS (55). Studies have 
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demonstrated that these S. salivarius strains are safe for human consumption (56), and 
can colonize and persist in the human oral cavity (57, 58), particularly on the tongue 
dorsum and other mucosal membranes. S. salivarius K12 has been shown in placebo 
controlled studies to prevent recurrent Streptococcal induced pharyngitis in adults (20 
patients receiving the probiotic for 90 days) (59) and children (45 patients receiving the 
probiotic for 90 days, then a 6 month follow-up period) (60), as well as reduce halitosis 
by limiting the production of volatile sulfur compounds from anaerobic bacteria (48). S. 
salivarius M18 consumption was able to reduce dental plaque scores and S. mutans 
numbers in children (61). 
 Given S. salivarius K12 and M18's successful ability in treating other oral 
diseases, our group was interested if this probiotic species could be used to target 
periodontal disease. Interestingly, a wide variety of Streptococci species have been 
shown to exhibit anti-inflammatory effects on human cells. For example, Kaci et al. have 
demonstrated that multiple S. salivarius and S. vestibularis isolates are capable of 
inhibiting the inflammatory response of TNF-α stimulated intestinal epithelial cells (62), 
and that intragastric administration of a live S. salivarius strain significantly inhibited 
inflammation in severe and moderate colitis mouse models (63). Similarly, groups have 
shown that S. salivarius, S. mitis, and S. sanguinis can reduce the release of the pro-
inflammatory cytokine IL-8 from pathogen stimulated human cells (64, 65). As 
periodontal disease is primarily inflammation driven, and S. salivarius K12 and M18 
have a proven record of safety and efficient colonization in the human oral cavity, we set 
out to determine whether these probiotic strains could potentially play a role in the 
management of this disease.    
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1.7 Hypothesis and Objectives 
 We hypothesize that Streptococcus salivarius strains K12 and M18 are capable of 
modulating inflammation in the oral cavity.  
 The objectives of this thesis are to: 
1. Characterize the ability of S. salivarius strains to interact with a variety of oral 
microbes.  
2. Investigate whether S. salivarius can modulate inflammatory factors produced by 
human oral fibroblasts exposed to common dental pathogens.  
3. Assess in humans the extent to which S. salivarius K12 administration can modulate 
the oral microbiome and inflammatory mediators over the course of 14 days.   
12 
 
Chapter 2  
2 Materials and Methods 
 
2.1 General Materials and Methods 
2.1.1 Bacterial Growth Media 
 All bacteriological media types were prepared according to the manufacturer's 
instructions, then sterilized by autoclaving at 121oC, 15 psi for 15 minutes.   
2.1.2 Bacterial Strains - Origin 
 Streptococcus salivarius K12 and M18, Candida albicans TIMM 1768, as well as 
the nine standard indicator strains used (I1 to I9) were kindly provided from the laboratory 
collection of Dr J. R. Tagg (University of Otago, Dunedin, New Zealand). These were 
Micrococcus luteus (I1), S. pyogenes M-type 52 (I2), Streptococcus constellatus (I3), 
Streptococcus uberis (I4), S. pyogenes M-type 4 (I5), Lactococcus lactis ssp. lactis (I6), S. 
pyogenes M-type 28 (I7), S. pyogenes M-type 87 (I8) and Streptococcus dysgalactiae (I9). 
Aggregatibacter actinomycetemcomitans Y4 (AA), Porphyromonas gingivalis 33277 
(PG), Fusobacterium nucleatum 10593 (FN), and Streptococcus mutans 25175 were 
purchased from ATCC. Lactobacillus reuteri RC-14, Lactobacillus plantarum Lp-2001, 
and Lactobacillus helveticus Lafti L10 were obtained from the Reid/Burton culture 
collection.  
2.1.3 Bacterial Strains - Storage and General Culture 
 Stock cultures were stored in 30% (v/v) glycerol in MRS (de Man, Rogosa and 
Sharpe) broth (Lactobacilli species) or Brain Heart Infusion with Yeast Extract (BHYE) 
broth (all other species) at -80oC, and regularly subcultured every two weeks on the 
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appropriate solid media. Solid media was prepared in 10cm petri dishes. S. salivarius 
K12 and M18, along with I1 to I9 were maintained on Columbia Blood Agar plates (CBA) 
(Difco Columbia Agar Base [BD]) supplemented with 0.1% CaCO3 and 5% (v/v) sheep's 
blood. L. reuteri, L. plantarum, and L. helveticus were maintained on MRS plates with 
1.5% agar. Unless otherwise noted, these species were routinely grown at 37oC in 5% 
CO2 in an anaerobic jar. C. albicans was cultured aerobically at 30oC on Sabouraud 
Dextrose Agar. A actinomycetemcomitans, P. gingivalis, and F. nucleatum were grown at 
37oC on BYHE with 1.5% agar in an anaerobic chamber containing 85% (v/v) N2, 10% 
(v/v) H2, and 5% (v/v) CO2. 
2.1.4 Primary Human Gingival Fibroblasts 
 Gingival fibroblasts were cultured from explanted tissue obtained from healthy 
volunteers undergoing periodontal procedures in the Oral Surgery Clinic at UWO in 
accordance with the guidelines of the University’s Research Ethics Board with informed 
patient consent. Fibroblasts from four separate patients were used in this thesis, and were 
routinely cultured in Minimum Essential Medium (MEM) supplemented with 10% FBS 
and 100 mM L-glutamine, at 5% CO2 and 37oC. Fibroblast passages between 4-9 were 
used for the studies. For experiments, fibroblasts were inoculated into the wells of a 24-
well plate and allowed to grow for 48 hours to reach confluency (approximately 5 x 105 
fibroblasts per mL).  
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2.2 S. salivarius Experiments in vitro 
2.2.1 Simultaneous Bacterial Antagonism 
 Simultaneous bacterial antagonism assays were conducted as previously described 
(53). Briefly, overnight cultures of pathogens of interest were swabbed evenly over the 
surface of a blood agar plate. K12 and M18 colonies were then stab inoculated into the 
agar. Plates were incubated for 48 hours at 5% CO2, then examined for zones of 
inhibition.  
2.2.2 Deferred Bacterial Antagonism 
 K12 or M18 were grown as a 1 cm wide streak on a blood agar plate for 18 hours. 
The bacterial growth was then removed from the plate, with the surface of the plate then 
sterilized for 20 minutes with chloroform vapour. After drying, indicator strains and oral 
pathogens were streaked across the plate perpendicular to the original growth. The plate 
was then incubated for 48 hours at 5% CO2, and examined for inhibitory activity.  
2.2.3 Co-aggregation 
 To determine whether K12 and M18 could co-aggregate with the oral pathogens, 
a qualitative visual assay was carried out. Overnight cultures of each bacterial strain were 
centrifuged (10 minutes at 3000 x g), washed three times in PBS, then resuspended in 
PBS to an equivalent Optical Density (1.0). Each periodontal pathogen was mixed with 
an equal volume of the test S. salivarius strain. The turbidity of the mixture was then 
recorded at 8 hours and given a score based on the observed aggregation. Known positive 
(Candida albicans) and negative (Streptococcus mutans) controls were carried out as 
well to act as a reference.  
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2.2.4 Attachment to Host Cells 
 K12 and M18 were tested for their ability to adhere to cultured monolayers of 
human gingival fibroblasts. Overnight bacterial cultures were centrifuged (10 minutes at 
3000 x g), washed three times in PBS, then resuspended in fibroblast growth media and 
added to the monolayers at a Multiplicity of Infection (MOI) of 25:1, and incubated for 8 
hours. The monolayers were then washed three times with sterile PBS to remove non-
adherent bacteria, then lysed with 0.1% Triton X-100. This concentration of Triton X-100 
was tested to ensure it completely lysed all fibroblasts, while not affecting bacterial 
viability. Remaining bacteria were then dilution plated on blood agar and allowed to 
grow overnight at 5% CO2.  
2.2.5 Pro-inflammatory Cytokine Release 
 Potential anti-inflammatory effects of S. salivarius K12 and M18 were examined 
using a gingival fibroblast challenge model. Briefly, fibroblasts were added to the wells 
of a 24 well plate and allowed to grow for 48 hours until they reached confluency. At this 
point, cultures of either the probiotic, pathogen, or a combination of strains were added to 
the fibroblasts at an MOI of 25:1. Bacteria were co-incubated with the fibroblasts for 8 
hours. After this time period, the culture supernatant was collected, centrifuged to clear 
debris, then stored at -20oC. Levels of the pro-inflammatory cytokines IL-6 and IL-8 
were then determined using a Luminex multiplex immunoassay kit.  
 To determine whether S. salivarius K12 produced any soluble anti-inflammatory 
factors, overnight K12 cultures were centrifuged, with the resulting supernatant filter-
sterilized, then applied to F. nucleatum stimulated fibroblasts for 8 hours. The level of 
IL-8 secretion was then determined using a commercial IL-8 ELISA kit. K12 supernatant 
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was also fractionated based on size (using a 10 kDa centricon filter), with both the <10  
kDa fraction and >10 kDa tested on stimulated fibroblasts. Based on the fact that S. 
salivarius is known to secrete some molecules to a higher degree when grown on a solid 
surface, a freeze thaw extract from a K12 bacterial lawn was prepared. In this procedure, 
an agar plate covered in bacterial growth is placed at -80oC for 4 hours, then allowed to 
thaw with the resulting liquid collected from the degraded matrix and filter sterilized. 
Finally, this freeze thaw extract was subjected to heat treatment (10 minutes at 80oC) and 
trypsin digest (10 minutes). 
2.3 C. albicans Experiments in vitro 
 Hyphae formation/C. albicans adhesion to 96-well plates was assessed after 3 
hours, by fixation of cells in 70% ethanol, followed by crystal violet staining and OD600 
reading as previously described (66). Sterile-filtered supernatant (SFS) collected from 
select probiotic strains grown anaerobically for 22 hours in YEPD were mixed 50:50 with 
YEPD (1% FBS), to maintain a constant concentration of FBS and YEPD between 
conditions. Pooled, sterile-filtered human saliva was also used as a mixture in some 
experiments. As well, previously established biofilms were washed carefully three times 
with PBS, with plates then incubated for a further 3 hours with probiotic culture 
supernatant mixtures, then assayed for attachment as before. 
 
2.4 Pilot Study on the Effects of a Probiotic Gum on the Healthy Oral Cavity 
2.4.1 Human Study Objective and Primary Outcome 
 The major objective of this section was to test our hypothesis that a protective 
anti-inflammatory effect would be produced in the saliva of individuals consuming a 
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probiotic gum tablet containing S. salivarius K12 bacteria. As such, our primary outcome 
of interest was observing levels of several pro-inflammatory cytokines important in oral 
disease conditions at various time points, and comparing these to levels in individuals 
chewing regular, non-probiotic gum. Additionally, we wanted to determine how effective 
S. salivarius K12 delivered in gum colonizes and persists in the oral cavity, and what, if 
any, effects this gum would have on the established oral microbiome.   
2.4.2 Ethics Statement 
 Details of the proposed pilot study were reviewed and approved by both the 
Health Sciences Research Ethics Board at the University of Western Ontario (Appendix 
1) and the Clinical Research Impact Committee at the Lawson Health Research Institute 
(Appendix 2). Each participant received a package explaining the relevant details of the 
study, were given the opportunity to have any questions of theirs answered, and signed a 
letter of consent prior to the commencement of the study (Appendix 3).  
2.4.3 Study Population and Recruitment 
 Recruitment of individuals between the ages of 20-60 years with general good 
oral health took place in London, Ontario. Recruitment posters (Appendix 4) were placed 
in the Lawson Health Research Institute, and emphasized a need for healthy individuals 
interested in being part of a short, two week study. Communication between the study 
coordinator and those interested in participating was carried out by phone and in person. 
Participants were excluded if they had any oral disease, an oral implanted device, were 
currently taking antibiotics, or had a dental appointment scheduled during the course of 
the study. 
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2.4.4 Study Design and Sample Collection 
 The study recruited twenty healthy adult volunteers, who were randomly assigned 
into two groups containing 10 individuals each, matched for sex and age. Participants 
received either probiotic CulturedCare™ with BLIS K12™ gum tablets (Group 1) or 
regular gum tablets lacking probiotic bacteria (Group 2). CulturedCare™ gum tablets are 
commercially available in Canada. Each individual was assigned a unique identifier code, 
to ensure anonymity and that we would be blinded to which group a sample belonged too.  
Both gum types were similar in taste, appearance, and texture. Participants were supplied 
enough gum tablets to last the duration of the study. Over the course of the next 15 days, 
participants followed the timeline detailed in the "Study Design Flowchart" (Appendix 
5). On Day 1 of the study, participants brushed their teeth at 8:00 AM, then collected 3 
mL of unstimulated saliva in a supplied 15 mL conical tube at 9:00 AM. This served as a 
baseline sample for the participant. Individuals then chewed one gum tablet for 10 
minutes, before discarding the material. This was the standard chewing procedure used 
throughout the study. A second piece was chewed following tooth brushing at 8:00 PM. 
On Days 1-7 participants followed this twice daily pattern of brushing/chewing. On Day 
8 a "wash-out" period begun, where participants followed the same tooth brushing 
pattern, but without gum tablet consumption. Additional saliva samples were collected at 
1:00 PM on Day 1, and at 9:00 AM on Days 2, 8, and 15. These time points corresponded 
to 4 Hours, 24 Hours, 7 Days, and 14 Days post first gum tablet exposure. All saliva 
samples were delivered by the participants to the Burton lab at the Lawson Health 
Research Institute where they were immediately aliquoted into 1.5 mL eppendorf tubes 
and stored at -80oC until use.    
19 
 
2.4.5 Salivary Pro-Inflammatory Cytokine Levels 
 Levels of pro-inflammatory cytokines (IL-6, IL-8, IL-1β, and IFN-γ) in the saliva 
of subjects in the probiotic gum group were measured using multiplexed immunoassay 
kits according to the manufacturers’ instructions (Bio-Rad Laboratories Inc., Hercules, 
CA). A Bio-Plex 200 readout system was used (Bio-Rad), which utilizes Luminex® 
xMAP fluorescent bead-based technology (Luminex Corporation, Austin, TX). Cytokine 
levels (pg/mL) were automatically calculated from standard curves using Bio-Plex 
Manager software (v. 4.1.1, Bio-Rad). 
2.4.6 DNA Extraction and PCR Amplification 
 DNA was extracted from the saliva samples using the PowerSoil®-htp 96 Well 
Soil DNA Isolation Kit (MoBio). The extraction was carried out as per the 
manufacturer’s protocol, with two changes; the addition of a 10-minute incubation step at 
65oC in a bead bath before the bead-beating step, and a doubling of the centrifugation 
times. 500 µL of saliva were used for the extractions. In total, 94 samples were extracted 
for sequencing. 
 Samples were PCR amplified for the V4 region of the 16S rRNA gene using 
barcoded primers as follows: V4L (forward) 5’ GTGCCAGC[CA]GCCGCGGTAA 3’ 
and V4R (reverse) 5’ GGACTAC[ATC][ACG]GGGT[AT]TCTAAT 3’. Amplification 
was carried out in a 42 µL reaction with 10 µL of each primer (3.2 pMol/µL stock), 20 
µL GoTaq hot start colorless master mix (Promega) and 2 µL extracted DNA. 
Thermocycling conditions were as follows: initial hot start activation at 95°C for 2 min, 
then 25 cycles of 1 minute at 95°C for denaturation, 1 minute 55°C for primer annealing, 
and 1 min at 72°C for extension. 
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2.4.7 Sequencing and Read Processing 
 PCR products were quantified with a Qubit 2.0 Flourometer and high sensitivity 
dsDNA specific fluorescent probes (Life Technologies). Samples were mixed at 
equimolar concentrations and purified with the QIAquick PCR Purification kit 
(QIAGEN). The pooled product was sent to the London Regional Genomics Centre 
(LRGC) for sequencing on the Illumina MiSeq platform using the 600-cycle kit to 
produce 2x300 paired-end reads. Using in-house Perl and Shell scripts, reads were 
retained if sequence matched the primer while allowing 2bp mismatches, and with perfect 
matches to expected sequence barcodes. Paired reads passing this filter were overlapped 
using pandaseq (https://github.com/neufeld/pandaseq) (67) to produce full-length V4 
sequences assigned by sample. Operational taxonomic units (OTUs) were constructed by 
clustering V4 reads at 97% sequence identity using USearch v. 7 
(http://www.drive5.com/usearch/) (68). OTUs were retained if they represented at least 
0.1% abundance of any one sample. The most abundant sequence in the cluster was used 
as the reference sequence for taxonomic classification. The reference OTU sequences 
were compared to the RDP database release 11.2 (https://rdp.cme.msu.edu) using 
Seqmatch v. 3 (69), and the lowest common taxonomy was retained out of the top 20 hits 
with an S_ab score ≥ 0.5. OTU sequences from differential taxonomic groups were 
further validated by BLAST (70) against the Human Oral Microbiome Database 
(HOMD) v. 13.2 (http://www.homd.org). 
2.4.8 Statistical and Exploratory Analyses 
 The OTU table with assigned taxonomies was imported into QIIME 
(http://qiime.org) (71) for exploratory analyses including summarizing reads to different 
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taxonomic levels, generating beta diversity with weighted UniFrac distance (72) based on 
OTU sequence alignment with MUSCLE (73), and principal coordinate analysis (PCoA). 
Bar, stripchart, and PCoA plots were generated using R (74). Between-group 
comparisons for differential microbiota analyses were conducted with ALDEx2 package 
(http://www.bioconductor.org/packages/release/bioc/html/ 
ALDEx2.html) (75) in R. Taxonomic clusters were considered differential between 
groups with an adjusted p-value ﹤ 0.01 using Welch’s t-test with Benjamini-Hochberg 
multiple test correction, and with an effect size ≥ 1.5. 
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Chapter 3 
3 Results 
 
3.1 S. salivarius Interaction with Oral Microbes 
3.1.1 Bacterial Antagonism 
 The first step in this investigation was to determine whether S. salivarius K12 and 
M18 could inhibit the growth of common oral bacterial species, especially those 
associated with disease conditions. In a simultaneous antagonism assay, with the 
probiotic of interest stab inoculated into an agar plate immediately after it had been 
swabbed with a given indicator strain, both K12 and M18 failed to inhibit the growth of 
P. gingivalis, F. nucleatum, A. actinomycetemcomitans, and C. albicans (Table 1). 
However, they did demonstrate strong inhibition against indicator strains I1 to I9. 
 Additionally, a deferred antagonism assay was conducted to determine if initial 
growth of a probiotic would result in the restriction of later indicator growth. Once again, 
K12 and M18 demonstrated strong inhibition of strains I1 to I9, while having no effect on 
growth of the four oral pathogens tested (Table 2). 
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 Producer Strain 
Indicator Strain S. salivarius K12 S. salivarius M18 
P. gingivalis - - 
F. nucleatum - - 
A. actinomycetemcomitans - - 
S. mutans - - 
C. albicans - - 
Micrococcus luteus (I1) ++ ++ 
 S. pyogenes M-type 52 (I2) ++ ++ 
Streptococcus constellatus (I3) ++ ++ 
Streptococcus uberis (I4) ++ ++ 
S. pyogenes M-type 4 (I5) ++ ++ 
Lactococcus lactis ssp. lactis (I6) ++ ++ 
S. pyogenes M-type 28 (I7) ++ ++ 
S. pyogenes M-type 87 (I8) ++ ++ 
Streptococcus dysgalactiae (I9) ++ ++ 
Table 1. Simultaneous Bacterial Antagonism. Inhibition after 48 hours of growth of S. 
salivarius K12/M18 and indicator strain on agar plates. The zone of inhibition of the 
indicator strain is indicated by: '-' no inhibition, '+' zone of inhibition diameter ≥ 3mm, 
'++' zone of inhibition  diameter ≥ 5mm. Results were consistent across the three 
experiments conducted.     
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 Producer Strain 
Indicator Strain S. salivarius K12 S. salivarius M18 
P. gingivalis - - 
F. nucleatum - - 
A. actinomycetemcomitans - - 
S. mutans - - 
C. albicans - - 
Micrococcus luteus (I1) ++ ++ 
 S. pyogenes M-type 52 (I2) ++ ++ 
Streptococcus constellatus (I3) ++ ++ 
Streptococcus uberis (I4) ++ ++ 
S. pyogenes M-type 4 (I5) ++ ++ 
Lactococcus lactis ssp. lactis (I6) ++ ++ 
S. pyogenes M-type 28 (I7) ++ ++ 
S. pyogenes M-type 87 (I8) ++ ++ 
Streptococcus dysgalactiae (I9) ++ ++ 
Table 2. Deferred Bacterial Antagonism. Inhibition after 18 hours of S. salivarius 
K12/M18 growth on agar plates, followed by 48 hours of incubation of the indicator 
streaks. The degree of inhibition of the indicator streaks is noted by: '-' no inhibition, '+' 
zone of inhibition is the same width as the producer streak, '++' zone of inhibition is at 
least 1.5 times the width of the producer streak. Results were consistent across the three 
experiments conducted.     
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3.1.2 Bacterial Co-aggregation    
 The ability of the S. salivarius strains to interact with the same oral microbes 
through co-aggregation was then examined. S. salivarius K12 and M18 displayed 
identical co-aggregation patterns (Table 3). Both co-aggregated moderately well with P. 
gingivalis and F. nucleatum, and weakly with A. actinomycetemcomitans. C. albicans co-
aggregated extremely strongly with the S. salivarius strains, while S. mutans 
demonstrated no noticeable co-aggregation. 
3.1.3 Bacterial Adherence to Human Oral Cells 
 Both S. salivarius K12 and M18 adhered to primary human gingival fibroblasts 
after co-incubation for 8 hours (Figure 1). There was no significant difference in 
attachment between the strains, with each resulting in approximately 30 bacterial cells 
adhered per fibroblast at the endpoint. The level of adherence for S. salivarius was 
significantly higher than demonstrated by L. reuteri, with less than 5 bacterial cells bound 
per fibroblast. Finally, S. mutans did not adhere at all to the gingival fibroblasts. 
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S. salivarius Strain 
Pathogen 
PG FN AA S. mutans C. albicans 
K12 ++ ++ + - +++ 
M18 ++ ++ + - +++ 
Table 3. Bacterial Co-aggregation. Ability of S. salivarius K12/M18 to co-aggregate in 
solution with various pathogens after 8 hours: “-“ no co-aggregation, evenly turbid 
suspension; “+’”weak precipitation with evenly turbid supernatant; “++”moderate 
precipitation with evenly turbid supernatant and evidence of flocculation; 
“+++”substantial precipitation with clear supernatant and some flocculation. Results were 
consistent across the three experiments conducted.     
 
 
Figure 1. Bacterial Adherence to Human Gingival Fibroblasts. Attachment of various 
bacterial species to primary human gingival fibroblasts in vitro following 8 hours co-
incubation. Assay was carried out in triplet on three separate occasions.  
(* p<0.05 compared to K12 attachment, unpaired t-test).  
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3.1.4 Prevention of C. albicans Adherence  
 The ability of several oral probiotics to inhibit the binding of yeast to a solid 
surface was explored. C. albicans was grown for three hours in the wells of a 96 well 
plate in either pure growth media, or with a mixture of probiotic culture supernatants. 
Microscopy was used to confirm that it was the hyphael form of C. albicans adhering to 
the bottom of the plastic wells. After this period of growth the level of attachment of C. 
albicans to the wells was determined using a crystal violet staining assay. The addition of 
supernatant from both S. salivarius K12 and M18 significantly reduced adherence of C. 
albicans to the wells (Figure 2). This was also observed with L. plantarum and L. 
helveticus supernatants, which almost completely abolished C. albicans attachment. 
Decreasing the amount of probiotic supernatant added (from 1/2 to 1/4 of the total growth 
media) was less effective, but still resulted in significant attachment reduction. 
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Figure 2. Adherence of C. albicans to 96-well Plates. Ability of C. albicans to attach to 
the wells of a 96-well plate after 3 hours of incubation in YEPD (Control) or a mixture of 
YEPD with either 1/2 or 1/4 bacterial culture supernatant. 'Neg. Ctrl': YEPD alone with 
no C. albicans. (** p<0.01 compared to control, One-way ANOVA with Dunnett's 
multiple comparison test).  
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 Based on the observation that the collected probiotic culture supernatants had a 
lower pH than the normal C. albicans growth media, we wanted to determine if a lowered 
pH could be solely responsible for the observed decrease in attachment. C. albicans was 
therefore grown for 3 hours in the plastic wells in YEPD with the pH balanced to varying 
levels between 4 and 9 (Figure 3). A clear trend was observed, with the lowest pH media 
significantly reducing attachment. As such, the probiotic supernatants were pH balanced 
to 7.0, with the same C. albicans adherence assay conducted. Balancing the pH of these 
supernatants resulted in no significant attachment decrease for any of the tested probiotics 
(Figure 4), suggesting that pH reduction of the supernatants by these probiotic strains is 
the primary cause of the observed yeast attachment interference.  
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Figure 3. Effect of pH on C. albicans Adherence. Attachment of C. albicans to a 96-
well plate after 3 hours of incubation in YEPD adjusted to various pH levels. (* p<0.05 
compared to control, One-way ANOVA with Dunnett's multiple comparison test).  
 
Figure 4. Effect of pH-Balanced Probiotic Supernatants on C. albicans Adherence. 
Attachment of C. albicans to a 96-well plate after 3 hours of incubation in a mixture of 
YEPD with bacterial culture supernatants adjusted to pH 7.0.  
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 With the success of using non-pH balanced supernatant from individual probiotic 
strains to decrease C. albicans adherence, we wanted to test whether using combinations 
of these probiotics would result in similar, or perhaps even enhanced reduction. Using 
combinations of S. salivarius M18, L. plantarum, and L. helveticus supernatants resulted 
in a significant decrease in C. albicans adherence compared to the control (Figure 5). 
This was the case regardless if the bacteria were grown together to produce a single 
supernatant, or grown separately with their supernatants combined after the fact. The 
addition of L. helveticus supernatant to a S. salivarius M18/L. plantarum mix resulted in 
further, though non-significant, adherence reduction. While these combinations were 
effective, they did not result in significantly lowered attachment compared to the use of 
their individual strains alone, although this may be due to the minimum detection limit of 
this assay. Of particular note, using supernatant from a C. albicans culture had no effect 
on yeast attachment, suggesting that nutrient deprivation in the probiotic supernatants 
was not an important factor.  
 Finally, in an effort to create an assay that more closely mimics conditions in the 
oral cavity, we integrated the use of pooled, filtered human saliva into the C. albicans 
attachment experiment. Adding saliva to either the regular growth media or C. albicans 
culture supernatant resulted in a significant increase in yeast attachment (Figure 6). As 
before, combinations of S. salivarius M18, L. plantarum, and L. helveticus supernatants 
were able to significantly reduce C. albicans adherence to the wells, with the addition of 
saliva not impeding this ability.  
 
 
32 
 
 
 
 
 
Figure 5. Impact of Probiotic Combinations on C. albicans Adherence. Attachment of 
C. albicans to a 96-well plate after 3 hours of incubation in a mixture of YEPD with 
multiple, non-pH balanced bacterial supernatants. Growth media was 50% YEPD, 50% 
supernatant (equal mixture of species). For growth conditions indicated by '+' in the bar 
label, the probiotic species were grown overnight together in the same culture to produce 
the resulting supernatant, rather than pooling supernatants from individually grown 
species. (** p<0.01 compared to control, One-way ANOVA with Dunnett's multiple 
comparison test).  
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Figure 6. Effect of Saliva on Supernatant Mediated Reduction in C. albicans 
Adherence. Attachment of C. albicans to a 96-well plate after 3 hours of incubation in a 
mixture of YEPD and pooled, filter sterilized human saliva, combined with multiple, 
bacterial supernatants. Growth media was 50% YEPD, 50% supernatant (equal mixture 
of species), with an equivalent volume of saliva where indicated. For growth conditions 
indicated by '+' in the bar label, the probiotic species were grown overnight together in 
the same culture to produce the resulting supernatant, rather than pooling supernatants 
from individually grown species. (* p<0.05, ** p<0.01 compared to control, One-way 
ANOVA with Dunnett's multiple comparison test).  
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3.1.5 Disruption of C. albicans Biofilms 
 While oral probiotic supernatants proved capable of preventing C. albicans from 
attaching effectively to plastic wells, we were also interested if they could remove yeast 
that had already adhered and formed a biofilm. C. albicans cultures were grown for 3 
hours in regular growth media as before, then had the media carefully aspirated and the 
wells washed briefly, before the addition of our probiotic supernatants of interest. The 
presence of a thick yeast biofilm was confirmed by microscopy before the addition of the 
supernatants. The plate was allowed to incubate for a further three hours, then assayed for 
C. albicans attachment using the same crystal violet staining protocol. When compared to 
the use of a C. albicans culture supernatant, combinations of S. salivarius M18, L. 
plantarum and L. helveticus supernatant significantly reduced the amount of remaining 
attached C. albicans (Figure 7).  
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Figure 7. Disruption of C. albicans Biofilms by Probiotic Supernatants. Adherence of 
pre-attached C. albicans to 96-well plates following 3 hour exposure to various bacterial 
culture supernatants. For media conditions indicated by '+' in the bar label, the probiotic 
species were grown overnight together in the same culture to produce the resulting 
supernatant, rather than pooling supernatants from individually grown species. (* p<0.05, 
** p<0.01 compared to control, One-way ANOVA with Dunnett's multiple comparison 
test).  
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S. salivarius Modulation of Inflammatory Factors 
3.1.6 Pro-inflammatory Cytokine Release in vitro 
 The three periodontal pathogens (P. gingivalis, A. actinomycetemcomitans, and F. 
nucleatum) were tested individually and in combination for their ability to stimulate the 
production of pro-inflammatory cytokines in primary human gingival fibroblasts in vitro. 
After co-incubation with the fibroblasts for 8 hours, all three significantly increased the 
release of both IL-6  and IL-8 (Figure 8) compared to the no bacteria control. The 
combination of three strains stimulated the most IL-6 production, while the triple 
combination was not significantly different from P. gingivalis production in the case of 
IL-8. In both cases A. actinomycetemcomitans was the least effective periodontal 
pathogen at stimulating the release of these pro-inflammatory cytokines. In contrast, 
exposing the fibroblasts to S. salivarius K12 or M18 did not result in any significant 
differences in IL-6 or IL-8 (Figure 8) production compared to the control. The 
concentration of cytokines produced was similar between both S. salivarius strains tested. 
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Figure 8. Stimulation of Cytokine Production From Human Gingival Fibroblasts. 
Concentration of IL-6 (A) and IL-8 (B) following 8 hour co-incubation of gingival 
fibroblasts with various oral bacteria (* p<0.05, ** p<0.01 compared to control, One-way 
ANOVA with Dunnett's multiple comparison test).  
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3.1.7 S. salivarius Reduction of Pathogen Driven Cytokine Release   
 Using the same in vitro model system with primary human gingival fibroblasts, 
the oral probiotics S. salivarius K12 and M18 were tested for their ability to reduce 
pathogen induced IL-6 and IL-8 production. The S. salivarius strains were applied either 
simultaneously with the pathogens, or pre-incubated with the fibroblasts 30 minutes 
before the pathogens were added. S. salivarius K12 and M18 were able to inhibit 
pathogen induced IL-6 secretion (Figure 9A). Significant reductions were seen under all 
conditions, with the exception of K12 pre- or co-incubated with P. gingivalis, and K12 or 
M18 co-incubated with F. nucleatum. The S. salivarius strains were also effective at 
reducing IL-8 secretion (Figure 9B), with significant reductions demonstrated for all 
conditions with P. gingivalis, F. nucleatum, and the three pathogen combination. 
Pretreatment with M18 also significantly reduced IL-8 secretion from A. 
actinomycetemcomitans stimulated fibroblasts. Importantly, under no circumstances did 
the addition of the S. salivarius K12 or M18 increase the production of IL-6 or IL-8 from 
pathogen stimulated fibroblasts. 
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Figure 9. S. salivarius Reduction of Pathogen Stimulated Cytokine Release. Ability 
of S. salivarius K12 and M18 to inhibit the production of IL-6 (A) or IL-8 (B) from 
human gingival fibroblasts when co-incubated (K12/M18) or administered prior to 
(K12P/M18P) oral pathogen exposure (* p<0.05, ** p<0.01 compared to control within 
each pathogen group, One-way ANOVA with Dunnett's multiple comparison test).      
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3.1.8 Mechanism of IL-8 Reduction  
 Attempts were made to elucidate the mechanism behind the ability of S. salivarius 
K12 and M18 to reduce the production of pro-inflammatory cytokines from pathogen 
stimulated human gingival fibroblasts. Based on patterns observed in previous 
experiments, the choice was made to focus on S. salivarius K12 inhibition of F. 
nucleatum induced IL-8 secretion. Once again, co-incubation of fibroblasts with F. 
nucleatum resulted in significantly higher IL-8 production compared to the no bacteria 
control, while K12 alone resulted in no significant changes (Figure 10). Likewise, adding 
S. salivarius K12 to F. nucleatum reduced the IL-8 concentration back to a level not 
significantly different than the control. Supernatant collected from an overnight S. 
salivarius K12 culture had no effect on F. nucleatum induced IL-8 levels, nor did the >10 
kDa fraction of this supernatant alone. However, the <10 kDa fraction of the supernatant 
was effective at significantly reducing the IL-8 concentration. A freeze/thaw extract of S. 
salivarius K12 grown as a lawn overnight on agar plates was also able to accomplish this. 
While heat treatment of this freeze thaw extract had no effect on its activity, treatment 
with trypsin abolished its anti-inflammatory properties.  
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Figure 10. Mechanism of S. salivarius K12 Mediated IL-8 Reduction. Concentration 
of IL-8 produced by human gingival fibroblasts after 8 hours under various conditions. 
"Sup"= Supernatant, "FT"=Freeze/Thaw, "FN"=Stimulated with F. nucleatum (* p<0.05 
compared to control, One-way ANOVA with Dunnett's multiple comparison test).                   
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3.2 Effect of Probiotic Gum Use in the Healthy Oral Cavity 
3.2.1 Oral Microbiome Changes in Response to Chewing Gum 
 After filtering and clustering sequenced reads at 97% identity, there were 476 
OTUs > 0.01% total abundance. A total number of 2,774,309 sequenced reads were 
included for analysis, with a median of 29,779 ± 13,630 reads per sample. These OTUs 
were further clustered by taxonomic lineage into 38 family groups of at least 0.05% 
abundance across all samples. The most abundant taxonomic families detected at >10% 
of total classified reads were: Porphyromonadaceae (17.95%), Pasteurellaceae (15.97%), 
Prevotellaceae (15.85%), and Veillonellaceae (11.22%), apparent in Figure 11. 
 The weighted UniFrac distance is one method to determine the relatedness of 
different microbiota. The distances between samples is relative to how similar the 
composition of the microbiota are as weighted by the abundance of each organism 
detected. Weighted uniFrac distances can be interpreted and plotted using principal 
coordinate analysis (PCoA) as shown in Figure 12.  The samples do not segregate by 
group (probiotic vs control) in examination of the first 3 components, which explain 
81.01% of the total variance in the data (top row, Figure 12). However, there is a distinct 
shift in the first component over time, with many of the 7 day and 14 day samples 
differentiating from the earlier time points (bottom row, Figure 12). 
 Figure 11. Oral Microbiota
composition using V4 16S rRNA gene sequencing of saliva collected at five time points 
for healthy volunteers chewing either 
probiotic (bottom plot) contro
subject ID number, and each bar in a cluster is an individual saliva sample ordered as 
baseline, 4 hours, 24 hours, 7 days, and 14 days. The black bar indicates an uncollected 
sample. Colours correspond to the proportion of assigned taxonomic family (listed in the 
legend on the right), ordered according to total abundance from bottom of the plot to top. 
Groups of sequences that are less than 0.05% abundance across all samples, or less than 
1% of sequences in an individual are grouped as “rem”. Unclassified families are labeled 
by their lowest classified taxonomic rank.
 
 
 
 Profiles Over Two Weeks of Gum Chewing
S. salivarius K12 probiotic gum (top plot) or non
l gum. Each cluster of bars is an individual identified by a 
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Figure 12. PCoA Plots for 
Two dimensional PCoA plots representing the first three components of variation 
between all saliva samples in the dataset. The first component in this analysis represents 
the most variation explained in the data (in this case 60.49%), with subsequent 
components representing the next largest variance in the data. Distances between points 
on the plot represent how similar 
abundance. Points on the plot that are closer in space are therefore more similar in their 
taxonomic distribution. 
coloured based on variable of interest (top 
point).   
  
 
All Saliva Samples Based on Weighted UniF
samples are in terms of microbiota composition
The top and bottom row plots are identical
- study group; bottom - sample collection time 
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To further examine the apparent time-dependent change in microbiota, the weighted 
UniFrac distance of all time points from individuals in both treatment groups compared 
to their baseline sample before treatment were plotted (Figure 13). The median weighted 
UniFrac distance increases over treatment time indicating a shift in the microbiota. 
Notably, a subset of the samples at 7 days and 14 days are very distinct from the others 
(outlier points at the top of the plot in Figure 13, and to the right of the plot in Figure 12, 
bottom row). 
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Figure 13. Change in β-Diversity Measured by Weighted UniFrac Over Time. 
Weighted UniFrac distance of each saliva microbiota sample compared to that 
individual's baseline sample at 4 hours, 24 hours, 7 days, and 14 days. A value of 0 would 
represent identical microbiota composition between samples, with a value of 1 
representing maximal microbiota differences. Sample points are coloured by study group 
(probiotic - red; control - blue). Lines represent the median UniFrac distance of a given 
time point. Microbiota compositions change over time (regardless of study group), with a 
subset of individuals changing drastically at 7 and 14 days. 
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 In order to test if there was any differential taxonomic abundances between 
groups, a compositional data analysis framework was required (75). Therefore the 
ALDEx2 toolset was employed to test for significant taxonomic difference between 
groups at the family level. There were no differences (Benjamini-Hochberg adjusted p-
value >0.01) between the probiotic and control groups at baseline, between the probiotic 
and control groups at study end-point (14 days), nor between these groups at any of the 
other sample collection time points. Therefore, the treatment groups were pooled to test 
for differences at end of study (14 days) compared to baseline. Presented in Table 4, there 
were four family-level taxonomic groups with a relative increase in abundance, and three 
with a relative decrease in abundance (Benjamini-Hochberg adjusted p-value <0.01 and 
effect size ≥ 1.5). Examination of the OTUs in the family groups by BLAST to the 
HOMDB revealed that most of the OTU sequences in Erysipelotrichaceae were similar 
(>80% sequence identity) to Erysipelothrix tonsillarum (HOT_484) or Solobacterium 
moorei (HOT_678). 
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Table 4. Taxonomic Groups With Significant Changes in Relative Abundance.   
 
 
 
 
 
 
 
 
 Family-level taxonomic group Wt-BH* Effect Size^ 
Relative 
increase  
Firmicutes;Erysipelotrichia;Erysipelotrichales;Erysipelotrichaceae 1.85E-08 2.04 
Bacteroidetes;Bacteroidia;Bacteroidales;Porphyromonadaceae2 4.48E-08 1.87 
Bacteroidetes;Bacteroidia;Bacteroidales;Bacteroidaceae 5.25E-06 1.57 
Bacteroidetes;Bacteroidia;Bacteroidales;Porphyromonadaceae 6.86E-07 1.51 
Relative 
decrease 
Fusobacteria;Fusobacteria;Fusobacteriales;Leptotrichiaceae 1.39E-05 -1.77 
Actinobacteria;Actinobacteria;Actinomycetales;Actinomycetaceae 1.74E-05 -1.61 
Bacteroidetes;Bacteroidia;Bacteroidales;Prevotellaceae 1.34E-05 -1.51 
 
*Corrected p-value from a paired Welch’s t-test using Benjamini-Hochberg procedure 
^The median effect size as estimated by ALDEx2 
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3.2.2 Changes in Pro-Inflammatory Cytokine Levels 
 Concentrations of four pro-inflammatory cytokines linked with periodontal 
disease were measured in the collected saliva of the nine subjects in the probiotic gum 
group at each time point. These were all healthy individuals with no overt oral diseases, 
however it has been demonstrated that everyone has some degree of these inflammatory 
cytokines present in their saliva, as they are important for regular immune regulation. 
Although cytokine concentrations were only measured for subjects chewing the probiotic 
gum, the fact that a baseline saliva sample was taken allowed us to determine if exposure 
to the probiotic would either raise or lower the amount of these cytokines. IL-8 levels 
were the highest in the saliva samples (mean concentration 426.72 pg/mL for all samples 
combined), while both IL-6 (8.32 pg/mL) and TNF-α (3.27 pg/mL) were present at much 
lower concentrations (Figure 14). No significant differences were observed between the 
concentration of a given cytokine when compared to another time point.  
 To determine if overall cytokine concentration variation between individuals was 
obscuring the effects of probiotic gum consumption, fold changes in cytokines within 
individuals were examined (Figure 15). However, no statistically significant differences 
were observed when the fold changes for all probiotic gum chewers were compared for 
any cytokine between any two time points.    
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Figure 14. Salivary Levels of Pro-Inflammatory Cytokines. Concentration (pg/mL) of 
IL-1β, IL-6, IL-8 and TNF-α (A-D) in collected saliva samples for the probiotic group at 
five time points. Cytokine levels for each sample were determined individually, with the 
mean concentration for all individuals plotted on these graphs. No significant differences 
were observed for a given cytokine when comparing concentrations at any two time 
points (One-Way repeated measures ANOVA).   
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Figure 15. Fold Changes in Cytokine Concentrations. Baseline saliva cytokine levels 
of IL-1β, IL-6, IL-8 and TNF-α (A-D) for every individual in the probiotic group were set 
to 1, with fold-changes from baseline at each subsequent time point calculated and 
plotted. No significant differences were observed for a given cytokine when comparing 
concentrations at any two time points (One-Way repeated measures ANOVA).   
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Chapter 4  
4 Discussion 
 
 This thesis has demonstrated that oral strains of Streptococcus salivarius are 
capable of interacting with other microbes known to cause disease in the oral cavity 
through a variety of mechanisms, and can also influence pathogen-stimulated production 
of inflammatory mediators. These are important findings, as in addition to characterizing 
basic properties of this species central to its ability to colonize and persist in the oral 
cavity, it included the first test of an S. salivarius probiotic strain's ability to modulate 
salivary markers of inflammation in humans.  
 Bacteria in the oral cavity are known to adhere to surfaces and to each other in the 
form of coaggregates and plaque biofilms. Given that no human has a sterile mouth, the 
question is how do most individuals ensure inflammation and infection is minimal? For 
many years, the simple presence, or increased abundance of certain bacterial species was 
believed to be the driving cause behind many oral diseases. For example, Streptococcus 
mutans was long presumed to be the primary etiological agent of caries (76), while 
Porphyromonas gingivalis, Tannerella forsythia, and Treponema denticola (categorized 
together as the "red complex") were closely linked with periodontal disease (77).  
However, recent studies using high throughput sequencing techniques have shown that 
these assumptions are over simplistic, with diseases often being polymicrobial in nature 
(78, 79), and can even vary in microbial compositions between individuals (80).  
Furthermore, a vast range of species are common constituents of both a healthy and 
diseased oral cavity, including members of Pasteurellaceae and Prevotellaceae (10, 81). 
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We confirm the high prevalence of these species in the saliva in our study performed on 
19 orally healthy adults. Notably, Streptococcaceae were relatively abundant in these 
subjects, and it is reasonable to assume that S. salivarius strains were among the species 
detected in this family, as this species is the predominant commensal Streptococcus in the 
oral cavity (82). While not conducted as part of this thesis, it would be possible to detect 
and quantify S. salivarius K12 specifically by qPCR with targeted, validated primers, in a 
manner similar to Burton et al. (83). This presence in healthy adults, as well as its known 
early colonization of the oral cavity and the existence of various bacteriocins with potent 
activity against common Gram-positive oral pathogens, has made it a species of potential 
to recalibrate an aberrant oral microbiota, and thus suggests its use as a probiotic. Indeed, 
the world's first two S. salivarius commercial probiotic strains, K12 and M18, were 
selected for their ability to adhere, coaggregate and inhibit the growth of various 
Streptococcus pyogenes species known to cause pharyngitis (84, 85).  
 Malodour, dental caries and gingivitis are symbolic of a dysbiotic oral 
microbiome whose metabolic activities eventually lead to disease symptoms. Perhaps 
even more concerning, it is the ability of these colonizing microorganisms to induce high 
levels of inflammation that leads to pain, discomfort, and severe forms of periodontal 
disease with subsequent loss of alveolar bone (86). We hypothesized that S. salivarius 
may confer some immuno-modulatory activity in addition to its other beneficial 
characteristics. To explore this, we used primary human gingival fibroblasts as an in vitro 
model cell line, as they are in close contact with bacteria in subgingival plaque in 
humans, and have been demonstrated as crucial for sustaining inflammation in 
periodontal disease (87).  We did indeed show that strains K12 and M18 were capable of 
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reducing oral pathogen-induced IL-6 and IL-8 levels, two of the most notable indicators 
of inflammation in this disease (25). This adds to a previous finding that showed anti-
inflammatory activity of K12, albeit against Salmonella and E. coli co-cultured with 
human bronchial epithelial cells (64).   
 There are several means by which this activity could be beneficial in the oral 
cavity. Firstly, the direct bacterial interaction with the epithelium could modulate 
cytokines and reduce inflammation. This has been demonstrated for a S. salivarius strain 
in the context of interaction with intestinal epithelial cells, with administration of live 
bacteria also managing to alleviate inflammation in a mouse model of induced colitis (62, 
63).  Such an effect may be mediated by how the organism interacts with receptors such 
as TLR2, or by interfering with the signal transduction pathways of the host cells (88), 
either directly or through soluble by-products. We showed that a heat-stable, trypsin-
labile component of the supernatant of K12 did indeed down-regulate pathogen-
stimulated IL-8 production. More work remains to be done to further isolate and 
characterize this compound, as well as to determine what other molecules produced by S. 
salivarius K12 may enhance or interfere with this compound's activity. This early work is 
encouraging, and while this phenomenon has so far not been described elsewhere for S. 
salivarius K12 specifically, it supports a finding by Sliepen et al. that supernatants from 
S. salivarius, Streptococcus mitis, and Streptococcus sanguinis species were capable of a 
similar effect (65). Importantly, we demonstrated this anti-inflammatory ability of K12 
supernatant against F. nucleatum, which has traditionally been recognized as a 
periodontal pathogen, and indeed has many pathogenic characteristics such as invasion of 
epithelial cells and induction of inflammatory cytokines from host oral tissues (89). It 
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might be argued that as S. salivarius is often located on the dorsal surface of the tongue 
(58), it would not readily gain access to sub-gingival sites or be in high abundance there, 
but its secreted by-products could still have an impact. If released into saliva, the 
proteinaceous compound would be expected to be present in saliva for sufficient time to 
reach different areas of the mouth. Proteins of similar size have been shown to persist in 
the saliva and interact with a variety of bacteria and host cells (90). Of course, altering 
IL-6 and IL-8 is not necessarily the only way that inflammation is driven, and we did not 
test TNF-α or IL-1β, nor evaluate cellular immunity in this in vitro model. In addition, 
some levels of IL-6 and IL-8 are necessary to maintain an immune system that protects 
against infection (86), so the intent would not be to completely abolish them.  
 The ultimate test of these effects can only be achieved by human studies. In that 
regard, we showed that the net effect on healthy subjects of exposure to K12 was to 
maintain normal individual levels of IL-6 and IL-8, as these pro-inflammatory cytokines 
did not increase or decrease in concentration compared to baseline levels when 
individuals chewed the probiotic gum. This is an indicator of maintaining homeostasis, 
and also safety of this probiotic. A future study could test this intervention on subjects 
with known inflammation (for example, patients with moderate gingivitis or fixed 
orthodontic appliances), and whose condition has not been alleviated by antimicrobial 
agents.  
 Another way that these substances produced by K12 could be beneficial, is 
through the organism's interaction with other bacteria. We showed that K12 and M18 
coaggregate with pathogenic strains that are known stimulators of inflammation. It is 
possible this coaggregation also played a role in reducing IL-6 and IL-8 levels. In other 
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words, the probiotics either inhibited production of the inflammatory stimulants, or they 
blocked their ability to trigger the host's reaction to them. It was outside the scope of this 
thesis to examine these possibilities, but they are both worthy of investigation. K12 or 
M18 could not inhibit actual production of lipotechoic acid or lipopolysaccharides, but it 
may interfere with their binding to host cells. One way to test this would be to add LTA 
or LPS to the streptococcal supernatant to see if there is inhibition.   
 In the human study, the volunteers brushed their teeth one hour before lozenge 
use; it would have been interesting to see if there was an effect by not brushing, and 
therefore allowing the K12 time to coaggregate with the existing biofilms, then see if an 
anti-inflammatory effect was conveyed. This might have more aptly simulate our in vitro 
experiments.   
 Another test of the mechanisms involved would be to allow the subjects to brush 
their teeth then immediately apply the probiotic. This was done previously with strain 
M18 in 75 volunteers (57). While this approach displaced the indigenous S. salivarius in 
some subjects, Illumina sequencing of the V6 region of the 16S rRNA gene showed that 
the overall composition of the oral microbiome was not modified. This is not unexpected 
since brushing does not remove all plaque biofilms, but by displacing indigenous strains, 
it may provide a more anti-inflammatory S. salivarius the opportunity to integrate into the 
niche and reduce overall inflammation. This remains to be tested. If a more thorough 
dental cleaning was undertaken (rather than simple brushing), it may be possible to have 
S. salivarius probiotic strains better colonize, and then deplete re-adhesion of pathogens, 
thereby also reducing the inflammatory processes. This is more of a competitive 
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exclusion approach against the oral pathogens, and its potential has been demonstrated 
for S. salivarius by others (61).   
 The findings with Candida albicans were also insightful for several reasons. Up 
until now, the S. salivarius K12 strain had been shown to inhibit adhesion of C. albicans 
to plastic surfaces and lower colonization in the mouth of rats (91). Our studies showed 
that the interference with the yeast  is not due to reducing growth, but rather it is due to 
inhibiting hyphal formation and adhesion to surfaces. This makes sense ecologically, as 
yeast are common inhabitants of a healthy mouth (17), but their abundance and 
pathogenesis are kept in check by the indigenous microbiota and host immune status. 
Although we did not use primers to detect C. albicans, none of the human volunteers had 
evidence of yeast infection before or after probiotic use, indicating that the treatment did 
not disrupt the inherent protective nature of the microbiota. However, our in vitro studies 
showed that the K12 and especially M18 supernatant disrupted the yeast biofilms and 
prevented transition to infectious hyphal form. This aligns with studies in the vagina, 
where application of probiotic lactobacilli affected C. albicans metabolic activity, and 
increased expression of stress-related genes (92).   
 The ability of oral probiotics to affect metabolic processes involved in infection 
remain to be thoroughly studied. It remains unknown which metabolites are released en 
masse by oral biofilms from healthy and non-healthy individuals, and how they influence 
health and inflammation. If species such as S. salivarius somehow control the amount 
and types of metabolic products, this would potentially make them a useful intervention 
in people whose plaque biofilms are recalcitrant. Metabolic by-products have been 
described in the oral cavity, for example hydrogen sulfide (H2S) gas produced by 
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degradation of proteins in the subgingival pocket, which is highly toxic and believed to 
have pro-inflammatory properties (93). It is one of the compounds associated with 
halitosis. The alleviation of this condition by probiotic S. salivarius K12 (48) indicates 
that the metabolism of pathogens is indeed affected. A range of amino acids, peptides, 
lipids and carbohydrates can be detected in the mouth and are potentially markers for 
decay (94). The culprits producing toxic metabolites in periodontitis appear to be P. 
gingivalis, T. forsythia, and T. denticola (95). Ultimately, the concentrations of bacterial 
metabolites are what causes symptoms and signs of disease, and stimulation of 
inflammation. Therefore, a better understanding of which metabolites (microbial and/or 
host) are influenced by probiotic application, and how these changes affect health of the 
host, represent a key next series of studies that are warranted. Studies using 
metatranscriptomics  (96) along with metabolomics will be particularly insightful to 
identify the organisms producing the toxic metabolites, and whether their genes are 
suppressed by various treatments. This is the approach taken in our lab, where we showed 
that Lactobacillus iners, present in the healthy vagina, adapts to the infectious bacterial 
vaginosis (BV) emergence and higher pH, by altering its metabolic pathway (97), while 
Gardnerella vaginalis produces compounds specific to the BV condition (McMillan et al. 
submitted).  
 The human study provided two other interesting observations. Firstly, it 
confirmed other recent studies showing a wide range of bacterial types present in the 
saliva (10, 12, 81). This is transforming our view of the oral cavity and dental practice. It 
was not long ago that S. mutans was taught in university classes to be the exclusive 
etiological agent of caries, and that only a few pathogens were responsible for the 
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majority of oral diseases. These had essentially followed the old microbiology concept of 
Koch's Postulates (98), whereby a single organism caused a disease and this could be 
reproduced by adding it back into the site. Rather, it is clear now that a wide range of 
organisms, in most cases acting as a collective, create environmental conditions (low pH, 
high sugars, toxins, inflammatory mediators) that result in diseases which present in a 
clinically similar fashion.  
 Secondly, although the application of probiotics daily for a short seven days did 
not appear to modulate the microbiota profiles of the volunteers, as has also been shown 
with probiotic yogurt and the gut microbiota (99), there was some signs of shifts at day 
14 regardless of whether the probiotic or control gum was being chewed. This was 
surprising because it suggests that regular gum use can impact the oral microbiota, above 
and beyond whether it contains sugar or not. It also demonstrated that the chewing action 
per se over-rode the probiotic effect. We postulate that the xylitol present in both gums, 
was responsible, as it has been shown to modulate the populations of cariogenic 
streptococci (100, 101). Xylitol is a sugar alcohol which does not kill the probiotic strain 
directly, but it may have caused a change in the coaggregated biofilms, such that it 
affected adherence of the probiotic strain, and dislodged the clumps containing the 
probiotic. Thus, it may be better to chew a xylitol gum, dislodge the biofilms, then chew 
a probiotic gum (without xylitol) to re-calibrate the microbiota. Such a study is worthy of 
investigation, although its practical implementation may be difficult since consumers are 
not likely to do such a double-use of a gum product.  
 Alternatively, the human study simply showed that the probiotic application was 
not effective, and the xylitol effects were artifacts. The latter is supported by a study of 
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children in which xylitol did not disrupt the oral microbiota when chewed twice daily 
(102). Clearly, other human studies are warranted, particularly in patients with chronic 
diseases.  If K12 or M18 were found not to be effective, it would question the importance 
of bacteriocin production in inhibiting growth of pathogens. If studies confirmed that 
K12 or M18 were effective, it need not be because they produce the bacteriocins. As 
these bacteriocins are on mega-plasmids, removal of the plasmids would allow such 
testing to occur. This has actually been achieved, and both K12 and M18 have been 
produced without their plasmids (53). It would now be useful to assess the supernatants 
of these strains to see if they affect pathogenic biofilms and inflammation. In that case, it 
would be best to mimic plaque, caries or periodontal conditions, using a grouping of say 
the ten most abundance pathogens found in these conditions. These are being identified 
now through sequencing methodologies.  
4.1 Overall Conclusions 
 This thesis has utilized a range of in vitro, high throughput sequencing and human 
approaches to understanding how probiotic streptococci can be considered to improve 
and maintain oral health. Both S. salivarius K12 and M18 appear to have characteristics 
capable of interfering with bacterial and yeast pathogens in the mouth, and in addition to 
modulating host inflammation responses. Both these strains are now sold in Canada and 
other countries without any adverse effects. Given this, opportunities exist for dental 
practitioners to monitor use of these products in a randomized, placebo-controlled 
manner, to determine if clinical benefits are indeed accrued. From a mechanistic 
perspective, more studies, as suggested herein, are warranted.  
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